LifeNet Health LifeSciences has launched new cell-based assay services for compound discovery. The addition of in vitro services – including cytotoxicity screenings, biocompatibility assays, and a novel microphysiological system (MPS) – complements and adds to LifeSciences commitment of bringing high-quality primary human cells and tissues to the research world.
The new service offerings, following the acquisition of IONTOX, a provider of in vitro toxicology expertise, will offer alternatives to animal testing that support safer and more effective novel compound discovery to a global client base in the pharmaceutical, cosmetic, chemical, tobacco, and food additive industries.
Microphysiological System (MPS)
Our in vitro integrated organ platform is a custom designed mesoscale plate for understanding systemic toxicity. The platform allows for culture and maintenance of 3 to 6 tissue systems with a simulated vascular system.
Cytotoxicity assays are used in the early stages of compound development and will give an indication of whether the substance will adversely affect the cells or tissue.
As part of the development of a medical device, its biocompatibility needs to be determined. Our in vitro assay offerings meet the International Organization for Standardization 10993-5. Cytotoxicity is determined by using an extraction from the medical device, direct association of the device with cells in culture, or by indirect association using a separating layer between the device and the cultured cells.